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Introduction: Arrythmogenic right ventricular cardiomyopathy (ARVC) is
an autosomic dominant disease with a variable penetrance. Based on 2010 task
force criteria, baselines characteristics of patients referred from 3 French cen-
ters were analyzed to identified risk factors for ventricular arrhythmias.
Methods: All patients with a diagnosis of ARVC referred from 3 academic
French centers between 2006 and 2014 were included. The diagnosis was
based on the 2010 Task Force. Occurrence of sustained ventricular arrhyth-
mias and date of last alive status were collected from each center.
Results: The population consisted in 259 patients (171 males, sex ratio
1.9) with a mean age at diagnosis of 40+/-17 years. The VA group is com-
posed of 61 patients (23.5%) who experienced at least 1.9 VT episodes. An
ICD was implanted in 59% of them.
Mean follow-up was 4.0 years in “no VA group” and 7.5 years in “VA
group” (p=0.0003).
Occurrence of syncope (OR=2.26, 95%CI [0.99-5.0], p=0.03) or VA
(OR=3.1, 95%CI[1.8-5.2], p<0.0001) and sustained or non-sustained VA
during exercise testing were associated (OR=4.2, 95%CI [0.90-19.5], p=0.03)
with VA during follow-up. We failed to identify any ECG parameter related
to the occurrence of VA.
Dilated right ventricular (RV) was significantly associated with VA during
follow-up (OR = 3.6, 95%CI [1.36;9.65], p=0.005). Severe RV dysfunction
was more often identified (10% vs 3%, p=0.06) in the “VA group” in echo-
cardiography. By MRI, RVEF was significantly lower in “VA group” (34.6%
vs 42.1%, p=0.03) but RV end diastolic volume and presence of akinesia or
dyskinesia were not significantly different between two groups.
Genetic screening is on-going for all patients. Genetic screening will be
performed using HaloPlex™ Target Enrichment System (Agilent Technolo-
gies) which allow the sequencing of 163 genes previously reported as
involved in cardiac arrhythmias, conduction defect and cardiomyopathies.
Conclusion: Occurrence of syncope and VA at baseline or during exercise
test are associated with occurrence of VA during follow-up. RV abnormalities
on echocardiography and MRI are significantly associated with VT.
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Deletion of QKP1507-1509 amino-acids in SCN5A gene product, the
main cardiac Na+ channel Nav1.5, is associated with a large phenotypic
spectrum of long QT syndrome (LQT3), dilated cardiomyopathy (DCM)
and high incidence of youth sudden death. This mutation does not affect
the peak Na+ current (INa) but rather increases the late/persistent Na+
current (INaL). In order to investigate the mechanisms implicated in the
phenotype observed on the mutation carriers, a knock-in mouse model pre-
senting the equivalent QKP1510-1512 mutation has been generated
(Scn5a+/ΔQKP).
Mouse ECGs were recorded weekly from the age of 3 weeks. Na+ current
was recorded with the whole cell patch-clamp technique in ventricular myo-
cytes isolated from 4-week-old mice. Histological analysis was performed in
paraffin sections of hearts of 4-week-old mice. At the age of 3 weeks, mice
were treated with acute administration of ranolazine (30mg/kg i.p.) or β-
blocker propranolol (0.3-1-3mg/kg i.p.) to suppress arrhythmias.
Scn5a+/ΔQKP mice in sinus rhythm displayed a prolonged QT interval
(QTc = 64±2ms vs. 42±1ms in controls) with a high incidence of spontaneous
ventricular extrasystoles and/or non-sustained tachycardia, leading to early
mortality. Structural analysis showed right ventricular DCM. Voltage-depen-
dent activation and inactivation properties were significantly altered in
Scn5a+/ΔQKP mice, leading to an increase in the arrhythmogenic Na+
window current. INaL was enhanced by more than 2-fold in myocytes from
Scn5a+/ΔQKP mice compared to control mice. At 3 weeks, ranolazine signi-
ficantly decreased QTc and suppressed arrhythmias whereas propranolol alone
had no beneficial effects.
Scn5a+/ΔQKP mice recapitulate a large part of the diverse clinical pheno-
type of patients carrying the equivalent mutation.
Our results show that the mutation induces a late Na+ current involved in
the arrhythmogenic process. Ranolazine, rather than β-blockers, could be a
good candidate for pharmacological treatment.
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Rationale: Brugada syndrome is a human hereditary cardiac disease
known to cause ventricular tachyarrhythmias (torsade de pointes) that can lead
to sudden death. In about 20% of the Brugada affected patients, mutations
have been identified in the gene encoding the Na+ ion channel, SCN5A. Up
to now, genotype-phenotype studies have been performed using heterologous
expression systems that lack the correct cellular context of a cardiomyocyte.
Human Induced Pluripotent stem cells (hiPSCs) offer a now new paradigm for
gene mutation characterization.
Objective: In this study, using cardiomyocytes differentiated from hiPSCs,
we have electrophysiologically characterized a previously undescribed muta-
tion in SCN5A gene, carried by a Brugada affected patient.
Methods and results: hiPSCs from a Brugada affected patient carrying the
N1722D mutation in SCN5A have been generated and validated. hiPSCs from
a healthy subject were used as control. Using patch clamp techniques, the bio-
physical properties of the Na+ channel and action potential characteristics
were evaluated in both cardiomyocytes differentiated from these hiPSCs and
in a mammalian expression system expressing the mutant channel. Prelimi-
nary data from both cellular models suggest a three-times reduction in Na+
current. The hiPSCs-derived cardiomyocytes revealed a specific action poten-
tial phenotype which is still under investigation.
Conclusion: Brugada syndrome modeling using hiPSCs-derived cardio-
myocytes suggests that this cellular model recapitulates the characteristics of
a loss-of-function Na+ channel mutation and that hiPSCs-derived cardio-
myocytes can be used as an accurate model for cardiac Na+ channel disease.
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